# Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy

> **NCT04582591** · PHASE2 · UNKNOWN · sponsor: **Zealand University Hospital** · enrollment: 54 (actual)

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy

## Interventions

- **DRUG:** Cannabidiol 100 MG/ML

## Key facts

- **NCT ID:** NCT04582591
- **Lead sponsor:** Zealand University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-03
- **Primary completion:** 2022-01-05
- **Final completion:** 2023-08-30
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2022-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582591, "Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04582591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*